Document Classification

Section Type: METHODS

Text: CHT-nave patients with measurable disease and impaired renal function (30 mL/min < glomerular filtration rate [GFR] < 60 mL/min) and/or performance status (PS) 2 were randomly assigned to receive either GC (gemcitabine 1, 000 mg/m (2) on days 1 and 8 and carboplatin area under the serum concentration-time curve [AUC] 4. 5) for 21 days or M-CAVI (methotrexate 30 mg/m (2) on days 1, 15, and 22 ; carboplatin AUC 4. 5 on day 1 ; and vinblastine 3 mg/m (2) on days 1, 15, and 22) for 28 days.